Urakami K, Okada A, Ohno K, Kitaguchi N, Tanaka S, Nakamura S, Takahashi K
Division of Neurology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan.
Tohoku J Exp Med. 1994 Nov;174(3):199-207. doi: 10.1620/tjem.174.199.
We studied amyloid beta protein precursor with Kunitz-type protease inhibitor domains (APPI) concentration in cerebrospinal fluid (CSF) and APPI mRNA in skin fibroblast in Alzheimer's disease (AD). The subjects consisted of AD, cerebrovascular dementia (VD) and age-matched controls. We measured the APPI concentration in the CSF by the trypsin antibody sandwich ELISA. APPI mRNA was examined by the RT-PCR technique. The CSF APPI concentration in AD was significantly higher than that of VD and controls. The CSF APPI concentration in AD was high in the initial stage of dementia and decreased during the course. The expression of APPI mRNA in skin fibroblasts in AD was also significantly higher than that of VD and controls. These results suggest that measurements of APPI levels in CSF and APPI mRNA in skin fibroblasts may be useful for early diagnosis of AD.
我们研究了阿尔茨海默病（AD）患者脑脊液（CSF）中含库尼茨型蛋白酶抑制剂结构域的淀粉样β蛋白前体（APPI）浓度以及皮肤成纤维细胞中的APPI mRNA。研究对象包括AD患者、脑血管性痴呆（VD）患者以及年龄匹配的对照组。我们采用胰蛋白酶抗体夹心ELISA法测定脑脊液中的APPI浓度。通过逆转录聚合酶链反应（RT-PCR）技术检测APPI mRNA。AD患者脑脊液中的APPI浓度显著高于VD患者和对照组。AD患者脑脊液中的APPI浓度在痴呆初期较高，病程中降低。AD患者皮肤成纤维细胞中APPI mRNA的表达也显著高于VD患者和对照组。这些结果表明，检测脑脊液中APPI水平以及皮肤成纤维细胞中的APPI mRNA可能有助于AD的早期诊断。
